A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy

References

• Beckham JC, Caldwell DS, Peterson BL, Pippen AM, Currie MS, Keefe FJ, et al. Disease severity in rheumatoid arthritis: relation-ships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353–61.
   PubMed Web of Science ®Google Scholar
• Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125–32.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–602.
   Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etaner-cept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised con-trolled trial. Lancet 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
   Google Scholar
• Gomez-Reino JJ, Carmona L. Switching TNF antagonists in pa-tients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
   Google Scholar
• Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Ftheumatol 2004; 31:1098–102.
   Google Scholar
• Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vol-lenhoven FtF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Ftheumatol 2005;34: 353–8.
   Google Scholar
• Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774–85.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Fticevuti L, et al. Defective mucosa' T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004;53:70–7.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid ar-thritis: Work disability: a prospective 18 year study of 823 patients. J Ftheumatol 1998;25:2108–17.
   Google Scholar
• Catrina Al, Trollmo C, af Klint E, Engstrom M, Lampa J, Her-mansson Y, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macro-phages, but not lymphocytes, in rheumatoid arthritis joints: ex-tended report. Arthritis Rheum 2005;52:61–72.
   Google Scholar
• Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Ftheumatol Suppl 2005;74:13–8.
   PubMedGoogle Scholar
• Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid ar-thritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Ftheumatol 2006;16:58–62.
   PubMedGoogle Scholar
• Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of in-terstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing anti-body. Mod Ftheumatol 2006;16:251–5.
   PubMedGoogle Scholar
• St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concen-trations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451–9.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Ftiel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a pro- spective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   Google Scholar
• Miyasaka N, Takeuchi T, Eguchi K. Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Ftheumatol 2005;15:4–8.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Coo-per NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: 315–24.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Gold-smith C, et al. American College of Ftheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Mac-farlane JD, et al. Therapeutic efficacy of multiple intravenous infu-sions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid ar-thritis. Arthritis Rheum 1998;41:1552–63.
   Google Scholar
• LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86:4220–4.
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443–53.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven FtF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63: 426–30.
   Google Scholar
• Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003;112:37–53.
   PubMedGoogle Scholar
• Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opin-ion. Joint Bone Spine 2006;73:388–95.
   PubMed Web of Science ®Google Scholar
• Curran MP, Perry CM. Tacrolimus: in patients with rheumatoid arthritis. Drugs 2005;65:993-1001; discussion 2–3.
   Google Scholar